(12) **Translation of European patent specification**

(11) **NO/EP 3060229 B1**

(19) NO

NORWAY

(51) Int Cl.

A61K 38/00 (2006.01) ***A61K 39/395 (2006.01)***
A61K 9/00 (2006.01) ***A61K 47/18 (2017.01)***
A61K 39/00 (2006.01) ***C07K 16/28 (2006.01)***

Norwegian Industrial Property Office

(45)	Translation Published	2021.10.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.08.25
(86)	European Application Nr.	14855343.1
(86)	European Filing Date	2014.10.23
(87)	The European Application's Publication Date	2016.08.31
(30)	Priority	2013.10.24, US, 201361895143 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	AstraZeneca AB, 151 85 Södertälje, Sverige
(72)	Inventor	LEACH, William, c/o Medimmune LLC One Medimmune Way, Gaithersburg, MD 20878, USA LEWUS, Rachael, c/o Medimmune LLC One Medimmune Way, Gaithersburg, MD 20878, USA MCGIVNEY, James, c/o Medimmune LLC One Medimmune Way, Gaithersburg, MD 20878, USA NEWELL, Kelcy, c/o Medimmune LLC One Medimmune Way, Gaithersburg, MD 20878, USA STEWART, Kevin Douglas, c/o Medimmune LLC One Medimmune Way, Gaithersburg, MD 20878, USA
(74)	Agent or Attorney	RWS, Europa House, Chiltern Park, Chiltern Hill, SL99FG CHALFONT ST PETER, Storbritannia

(54) Title **STABLE, AQUEOUS ANTIBODY FORMULATIONS**

(56) References Cited:

WO-A1-2013/059408, WO-A2-2015/023507, US-A1- 2010 074 903, US-A1- 2009 304 706, US-A1- 2007 048 304, WO-A1-2013/063510, WO-A1-2015/023504, US-A1- 2010 291 073, US-A1- 2013 109 807,

NARASIMHAN CHAKRAVARTHY ET AL: "High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective", THERAPEUTIC DELI, FUTURE SCIENCE LTD, GB, vol. 3, no. 7, 1 July 2012 (2012-07-01), pages 889-900, XP009179763, ISSN: 2041-5990, DOI: 10.4155/TDE.12.68

Anonymous: "AstraZeneca advances Medimmune's benralizumab to Phase III in severe asthma

- Cambridge Network", , 31 October 2013 (2013-10-31), XP055388189, Retrieved from the Internet: URL:https://www.cambridgenetwork.co.uk/new s/medimmunes-benralizumab-to-phase-iii/ [retrieved on 2017-07-05]
DAUGHERTY A L ET AL: "Formulation and delivery issues for monoclonal antibody therapeutics", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 58, no. 5-6, 7 August 2006 (2006-08-07), pages 686-706, XP024892149, ISSN: 0169-409X, DOI: 10.1016/J.ADDR.2006.03.011 [retrieved on 2006-08-07]

Patentkrav

1. Stabil vandig antistofformulering som ikke har vært utsatt for temperaturer under frysepunktet og omfatter:

a. 30 mg/ml av et antistoff, idet antistoffet omfatter en tung kjede som omfatter SEKV.-IDNR.: 4 og en lett kjede som omfatter SEKV.-IDNR.: 2, og

b. 0,006 % polysorbat-20, og

c. 20 mM histidin/histidin-HCl, og

d. 250 mM trehalose, idet pH i formuleringen er 6,0.

2. Antistofformuleringen ifølge krav 1, idet formuleringen er en injiserbar formulering, idet formuleringen eventuelt egner seg for intravenøs, subkutan eller intramuskulær administrering.

3. Beholder med tett lokk som inneholder antistofformuleringen ifølge krav 1 eller 2.

4. Farmasøytisk enhetsdoseform som egner seg for parenteral administrering hos et menneske, idet enhetsdoseformen omfatter antistofformuleringen ifølge ett av kravene 1 til 3 i en egnet beholder, idet den egnede beholderen eventuelt er en forhåndsfylt sprøyte.